GeneBioTech (Korea) Probability of Future Stock Price Finishing Over 4310.0
| 086060 Stock | KRW 3,475 10.00 0.29% |
GeneBioTech |
GeneBioTech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GeneBioTech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GeneBioTech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 62.81 B. Net Loss for the year was (484.4 M) with profit before overhead, payroll, taxes, and interest of 9.43 B. | |
| GeneBioTech Co has accumulated about 7.43 B in cash with (2.84 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
GeneBioTech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GeneBioTech Stock often depends not only on the future outlook of the current and potential GeneBioTech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GeneBioTech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.6 M | |
| Cash And Short Term Investments | 14.3 B |
GeneBioTech Technical Analysis
GeneBioTech's future price can be derived by breaking down and analyzing its technical indicators over time. GeneBioTech Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of GeneBioTech Co. In general, you should focus on analyzing GeneBioTech Stock price patterns and their correlations with different microeconomic environments and drivers.
GeneBioTech Predictive Forecast Models
GeneBioTech's time-series forecasting models is one of many GeneBioTech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary GeneBioTech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about GeneBioTech
Checking the ongoing alerts about GeneBioTech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for GeneBioTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the revenue of 62.81 B. Net Loss for the year was (484.4 M) with profit before overhead, payroll, taxes, and interest of 9.43 B. | |
| GeneBioTech Co has accumulated about 7.43 B in cash with (2.84 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
Other Information on Investing in GeneBioTech Stock
GeneBioTech financial ratios help investors to determine whether GeneBioTech Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GeneBioTech with respect to the benefits of owning GeneBioTech security.